Unverified88% confidenceDecision RuleTime unknown
合并冠心病、心绞痛或心衰的高血压患者，β受体阻滞剂(洛尔类)和ACEI/ARB有额外获益；但哮喘、严重心动过缓、二度以上房室传导阻滞者慎用β阻滞剂
1
Sources
88%
Confidence
Long-term
Relevance
-
First Seen
Sources
Related Entities
Related Claims
Unverified如果同时在意降压效果和心血管保护但无法耐受干咳，应优先考虑ARB类（如缬沙坦、厄贝沙坦）；如果能耐受干咳且合并冠心病/心衰，雅施达是循证优选77% similarPartially Verified哮喘或支气管痉挛患者禁用，β受体阻滞剂会加重气道收缩75% similarUnverified相比普利类(ACEI)无干咳副作用，但降压强度在单药使用时可能略逊于氨氯地平等钙拮抗剂，血压较高者常需联合用药75% similarUnverified普利类(ACEI)约10-20%患者出现干咳副作用，若无法耐受可换用沙坦类(ARB)，两者机制相近但ARB极少引起干咳，且不可两者联用72% similarUnverified合并糖尿病或蛋白尿(肾病)的高血压患者，优先选用ACE抑制剂(普利类)或ARB(沙坦类)，因其具有独立于降压之外的肾脏保护作用70% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/203796API
curl https://kongchang.com/api/v1/knowledge/claims/203796MCP
get_claim(id=203796)